Joint Hypermobility Not Associated With Chronic Low Back Pain, Lumbar OA
Joint hypermobility may not be associated with chronic low back pain or lumbar osteoarthritis.
Pain Management
CDC Provides Clarification of Opioid Prescribing Guideline
Implementation of the U.S. Centers for Disease Control and Prevention opioid prescribing recommendations should be consistent with the guideline’s intent.
Pain Trajectories Predict Disabilities Affecting Daily Living in Arthritis
Improvements in pain in older adults with arthritis may not be associated with improvements in 2 of 3 domains of disability.
FDA Launches “Remove the Risk” Campaign for Safe Disposal of Unused Opioids
The U.S. Food and Drug Administration is launching on April 25, 2019, its “Remove the Risk” campaign, aimed at promoting the safe disposal of unused opioids.
Physical Activity-Adjusted Pain Score Optimal for Functional Assessment of Knee OA
Physical activity-adjusted pain measures may be associated with the severity of radiographic knee osteoarthritis, and be helpful for the assessment of functional capacity in these patients.
Analgesic Prescribing Changes Not Associated With Reported Changes in OA Pain Among Veterans
Researchers examined pain intensity ratings in veterans with OA to determine if changes in published analgesic policies and initiatives affect patient outcomes.
Experimental Pain Variability May Predict Response to Drug vs Placebo in OA Clinical Trials
Experimental pain variability in clinical trials may be more accurate at predicting response to treatment vs placebo.
Comparing Clinical vs Ultrasound Findings of Ankle Pain in Rheumatoid Arthritis
Researchers examined the prevalence and distribution of clinical and ultrasound pathologic findings at ankle level in patients with rheumatoid arthritis.
Pain Coping Skills Training Improves Pain Management, Perception in African American Patients With OA
The program did not significantly reduce pain, but did improve key measures of pain coping and perceived ability to manage pain in African American patients with osteoarthritis.
Mixed Results for Tanezumab in Phase 3 Osteoarthritis Trial
Pfizer announced topline results from a long-term phase 3 study of tanezumab in patients with moderate to severe osteoarthritis (OA) of the hip or knee.
Next post in Pain Management
